Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
Phase 1 Study of Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
Sponsor: PharmaEngine
A PHASE1 clinical study on Refractory Solid Tumors, this trial is completed. The trial is conducted by PharmaEngine and has accumulated 12 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Aug 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
-
Jan 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
-
Oct 2021 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- PharmaEngine
For direct contact, visit the study record on ClinicalTrials.gov .